This Article Full Text Full Text (PDF) All Versions of this Article: 37/10/2644    most recent 01.STR.0000241106.81293.2bv1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Koziol, J. A. Articles by Feng, A. C. Search for Related Content PubMed PubMed Citation Articles by Koziol, J. A. Articles by Feng, A. C. Related Collections Other Stroke Treatment - Medical

(Stroke. 2006;37:2644.)
© 2006 American Heart Association, Inc.

Comments, Opinions, and Reviews

On the Analysis and Interpretation of Outcome Measures in Stroke Clinical Trials

Lessons From the SAINT I Study of NXY-059 for Acute Ischemic Stroke

From the Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, Calif.

Correspondence to James A. Koziol, PhD, The Scripps Research Institute, 10550 North Torrey Pines Road, MEM216, La Jolla, CA 92037. E-mail koziol{at}scripps.edu

Background and Purpose— A variety of primary end points have been used in acute stroke trials. We focus on the modified Rankin Scale, a reliable and valid ordinal outcome measure that assesses disability on a 7-point scale.

Methods— We provide an abbreviated discussion of analytical methods for ordinal scales, and related effect size measures; we illustrate these methods and their interpretation with outcome data from the SAINT I study of NXY-059 in acute ischemic stroke.

Results— The nonparametric Mann-Whitney statistic provides a straightforward method for analysis of the modified Rankin Scale, and incorporates associated measures of effect size. These measures are directly related to the concepts of Number Needed to Treat and Number Needed to Harm.

Conclusions— Our re-examination of the outcome data from the SAINT I study provides little evidence for the purported efficacy of NXY-059. More broadly, analysis and interpretation of ordinal outcome scales based on ascribed numerical values to the steps of the scale should be done cautiously. Statistical treatment of multiple primary outcome measures in acute stroke clinical trials should be established before analysis. Lastly, conflating statistical and clinical significance should be avoided.

Key Words: Mann-Whitney statistics • numbers needed to treat or harm

This article has been cited by other articles:

				S. W. Miller and Y. Y. Palesch Comments Regarding the Recent OAST Article Stroke, January 1, 2008; 39(1): e14 - e14. [Full Text] [PDF]

				M. D. Ginsberg Response to Letter by Fisher et al Stroke, November 1, 2007; 38(11): e128 - e128. [Full Text] [PDF]

				A. I. Faden and B. Stoica Neuroprotection: Challenges and Opportunities Arch Neurol, June 1, 2007; 64(6): 794 - 800. [Abstract] [Full Text] [PDF]

				M. D. Ginsberg Life After Cerovive: A Personal Perspective on Ischemic Neuroprotection in the Post-NXY-059 Era Stroke, June 1, 2007; 38(6): 1967 - 1972. [Abstract] [Full Text] [PDF]

				G. J. del Zoppo and J. A. Koziol Recanalization and Stroke Outcome Circulation, May 22, 2007; 115(20): 2602 - 2605. [Full Text] [PDF]

				J. L. Saver Deriving Number-Needed-to-Treat and Number-Needed-to-Harm From the Saint I Trial Results Stroke, February 1, 2007; 38(2): 257 - 257. [Full Text] [PDF]

				J. A. Koziol and A. C. Feng Response to Letter by Saver Stroke, February 1, 2007; 38(2): 258 - 258. [Full Text] [PDF]